Immunotherapy

A randomized trial showed that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) has some promise for the frontline treatment of some patients with RCC.

Three recent trials showed that Keytruda had a durable response for patients with a rare subtype of melanoma.

Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.

Roy Herbst, M.D., Ph.D., spoke with CURE about the future of Keytruda, and immunotherapy in general, to treat lung cancer.

Immunotherapy agents have their own set of side effects, and managing them quickly and efficiently is key.

How and why I've chosen to live my cancer in the public eye.

Growing scientific insights have led to the swift development of treatments for advanced melanoma, leaving doctors to iron out details about their application.

The role of immunotherapies and targeted treatments in lung cancer is evolving at breakneck speed.

Keytruda improved quality of life for patients with lung cancer in a recent trial.

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

Immunotherapy continues to advance in melanoma and other solid tumor types as new combinations and biomarkers are being explored.

Keytruda may be a viable treatment option for patients with advanced microsatellite instability-high cancer in the future.

The future of multiple myeloma treatment may be in immunotherapy combinations, according to Eric L. Smith, M.D., Ph.D.

A cancer diagnosis comes served up with a slew of side effects. While many can be anticipated and managed, some cannot. They can crop up unexpectedly and take up residence indefinitely.

Checkpoint inhibitors such as Opdivo and Yervoy are showing promise in treating MDS and AML.

Single-agent Keytruda improved survival rates for a group of patients with lung cancer, according to the results of a recent study presented at the 2016 European Society for Medical Oncology (ESMO) Congress.

Immunotherapy agents have shown significant promise in treating non-small cell lung cancer (NSCLC) in the second line, but what will their future be in lung cancer's frontline?

Winson Cheung, M.D., medical oncologist at the British Columbia Cancer Agency in Vancouver, discusses the importance of discussing any immunotherapy-related side effects with health care providers.

For decades, research into bladder cancer treatments was stagnant, but now science has moved into a period rife with new approaches — immunotherapy chief among them.

CURE spoke with Yvonee Saenger about the future use of Opdivo and Yervoy in melanoma.

The FDA granted Keytruda a priority review for the first-line treatment of some patients with NSCLC.

According to recent findings from a phase 3 trial, the immunotherapy Tecentriq (atezolizumab) improved survival compared with docetaxel in patients with advanced non–small cell lung cancer (NSCLC) following the failure of platinum-based chemotherapy.

The facts and figures of what the trajectory of a melanoma diagnosis looks like.